首页> 美国卫生研究院文献>World Journal of Gastroenterology >Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: The Freiburg experience (1989-2002)
【2h】

Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: The Freiburg experience (1989-2002)

机译:II期和III期直肠腺癌的辅助和新辅助放化疗中的贫血和长期结果:弗莱堡的经验(1989-2002)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

AIM: To evaluate the long-term outcome of standard 5-FU based adjuvant or neoadjuvant radiochemotherapy and to identify the predictive factors, especially anemia before and after radiotherapy as well as hemoglobin increase or decrease during radiotherapy.METHODS: Two hundred and eighty-six patients with Union International Contre Cancer (UICC) stage II and III rectal adenocarcinomas, who underwent resection by conventional surgical techniques (low anterior or abdominoperineal resection), received either postoperative (n = 233) or preoperative (n = 53) radiochemotherapy from January 1989 until July 2002. Overall survival (OAS), cancer-specific survival (CSS), disease-free survival (DFS), local-relapse-free (LRS) and distant-relapse-free survival (DRS) were evaluated using Kaplan-Meier, Log-rank test and Cox’s proportional hazards as statistical methods. Multivariate analysis was used to identify prognostic factors. Median follow-up time was 8 years.RESULTS: Anemia before radiochemotherapy was an independent prognostic factor for improved DFS (risk ratio 0.76, P = 0.04) as well as stage, grading, R status (free radial margins), type of surgery, carcinoembryonic antigen (CEA) levels, and gender. The univariate analysis revealed that anemia was associated with impaired LRS (better local control) but with improved DFS. In contrast, hemoglobin decrease during radiotherapy was an independent risk factor for DFS (risk ratio 1.97, P = 0.04). During radiotherapy, only 30.8% of R0-resected patients suffered from hemoglobin decrease compared to 55.6% if R1/2 resection was performed (P = 0.04). The 5-year OAS, CSS, DFS, LRS and DRS were 47.0%, 60.0%, 41.4%, 67.2%, and 84.3%, respectively. Significant differences between preoperative and postoperative radiochemotherapy were not found.CONCLUSION : Anemia before radiochemotherapy and hemoglobin decrease during radiotherapy have no predictive value for the outcome of rectal cancer. Stage, grading, R status (free radial margins), type of surgery, CEA levels, and gender have predictive value for the outcome of rectal cancer.
机译:目的:评估标准的基于5-FU的辅助或新辅助放疗的长期结果,并确定预测因素,尤其是放疗前后的贫血以及放疗期间血红蛋白的增加或减少。方法:286于1989年1月开始接受常规手术技术(低位前切除或腹部手术切除)的联合国际直肠癌(UICC)II期和III期直肠腺癌患者接受术后放疗(n = 233)或术前(n = 53)直至2002年7月。使用Kaplan-Meier评估了总生存期(OAS),癌症特异性生存期(CSS),无病生存期(DFS),无局部复发生存期(LRS)和无远处复发生存期(DRS)。 ,对数秩检验和Cox比例风险作为统计方法。多因素分析用于确定预后因素。中位随访时间为8年。结果:放化疗前的贫血是改善DFS(危险比0.76,P = 0.04)以及分期,分级,R状态(游离radial骨边缘),手术类型,癌胚抗原(CEA)的水平和性别。单因素分析表明,贫血与LRS受损(局部控制较好)有关,但DFS改善。相反,放疗期间血红蛋白减少是DFS的独立危险因素(危险比1.97,P,= 0.04)。在放疗期间,R0切除的患者中只有30.8%的血红蛋白减少,而进行R1 / 2切除的患者则减少了55.6%(P = 0.04)。五年OAS,CSS,DFS,LRS和DRS分别为47.0%,60.0%,41.4%,67.2%和84.3%。结论:放疗前的贫血和放疗期间血红蛋白的降低对直肠癌的预后没有预测价值。分期,分级,R状态(游离radial骨边缘),手术类型,CEA水平和性别对直肠癌的结局具有预测价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号